A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Status:
Recruiting
Trial end date:
2024-01-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability,
pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with
Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic
cancer.